thrombotic complications of cardiovascular disease are a main cause of death and disability and , consequently , thrombolytic therapy with plasminogen activators could favorably influence the outcome of such life-threatening diseases as acute myocardial infarction ( ami ) .
C0007226
cardiovascular
C0155626
acute